Results 141 to 150 of about 1,629 (181)

Natural products modulating MAPK for CRC treatment: a promising strategy. [PDF]

Front Pharmacol
Zhou L, Zhang J, Zhao K, Chen B, Sun Z.
europepmc   +1 more source

Autophagy in doxorubicin resistance: basic concepts, therapeutic perspectives and clinical translation. [PDF]

Front Immunol
Zhang Y, Ji Y, Tu Y, Li Y.
europepmc   +1 more source

PeriTox-M, a Cell-Based Assay for Peripheral Neurotoxicity with Improved Sensitivity to Mitochondrial Inhibitors. [PDF]

Cells
Holzer AK, Dürr M, Multrus S, Dangel L, Magel V, Leist M.   +5 more
europepmc   +1 more source

Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions. [PDF]

Sci Adv
Flickinger KM, Wilson KM, Rossiter NJ, Hunger AL, Vishwasrao PV, Lee TD, Mellado Fritz CA, Richards RM, Hall MD, Cantor JR.   +9 more
europepmc   +1 more source

COPB2 as a key regulator of cell growth in human osteosarcoma cells: Potential therapeutic target and prognostic indicator. [PDF]

J Bone Oncol
Cui Y, Shi X, Wang Q, Wu W, Pan Y, Wang B, Lei M.   +6 more
europepmc   +1 more source

Data mining of PubChem bioassay records reveals diverse OXPHOS inhibitory chemotypes as potential therapeutic agents against ovarian cancer. [PDF]

J Cheminform
Sharma S, Feng L, Boonpattrawong N, Kapur A, Barroilhet L, Patankar MS, Ericksen SS.   +6 more
europepmc   +1 more source

Neurofibromatosis Type 1 and the Search for Effective Tumor Therapies Using High-Throughput Drug Screening. [PDF]

Curr Oncol
Bouley SJ, Housden BE, Walker JA.
europepmc   +1 more source

The multifaceted role of PUMA in cell death pathways: its therapeutic potential across cancer types. [PDF]

Cell Commun Signal
Tat SS, Mandal K, Sharma T, Ghate NB, Barik GK, Gachhe RN, Santra MK.   +6 more
europepmc   +1 more source

Investigation of a cryptic ligand binding site on Plasmodium falciparum Hsp90. [PDF]

Bioorg Med Chem
Mansfield CR, Taggart EL, Chirgwin ME, Derbyshire ER.   +3 more
europepmc   +1 more source